Advances in Chronic Kidney Disease
Volume 13, Issue 1 , Pages 47-55 , January 2006

Calcineurin Nephrotoxicity

  • David Williams
    • ,
  • Lukas Haragsim

      Affiliations

    • Corresponding Author InformationAddress correspondence to Lukas Haragsim, MD, Associate Professor of Medicine, University of Oklahoma Health Science Center, 920 Stanton L. Young Blvd., WP-2250 Oklahoma City, OK 73104.

References 

  1. Solez K , Vincenti F , Filo R . Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine . Transplantation . 1998;66:1736–1740
  2. Meier-Kriesche H , Schold J , Kaplan B . Long-term renal allograft survival (Have we made significant progress or is it time to rethink our analytic and therapeutic strategies?) . Am J Transplant . 2004;4:1289–1295
  3. Melk A , Halloran P . Immunosuppressive Agents Used in Transplantation . In:  Johnson RJ editors. Comprehensive Clinical Nephrology . Philadelphia, PA: Mosby; 2000;p. 1057–1069
  4. Johnson RJ , Alpers CE , Yoshimura A , et al.   Renal Injury from angiotensin II mediated hypertension . Hypertension . 1992;19:464–474
  5. Lassila M . Interaction of cyclosporine A and the renin-angiotensin system (New perspectives) . Curr Drug Metab . 2002;3:61–71
  6. Barros EJ , Boim MA , Ajzen H , et al.   Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicity . Kidney Int . 1987;32:19–25
  7. Murray BM , Paller MS , Ferris TF . Effect of cyclosporine administration on renal hemodynamics in conscious rats . Kidney Int . 1985;28:767–774
  8. Pichler R , Franceschini N , Young B , et al.   Pathogenesis of cyclosporine nephropathy (Roles of angiotensin II and osteopontin) . J Am Soc Nephrol . 1995;6:1186–1196
  9. Von Willebrand E , Hayry P , Ahonen J . Differential diagnosis of cyclosporine nephrotoxicity versus rejection by fine needle aspiration biopsy . Kidney Int . 1983;24:418
  10. Von Willebrand E , Hayry P . Cyclosporine A deposits in renal allografts . Lancet . 1983;2:189–192
  11. Perico N , Remuzzi G . Cyclosporine-induced renal dysfunction in experimental animals and humans . Transplant Rev . 1991;5:63–80
  12. Conger JD , Kim GE , Robinette JB . Effects of Ang II, ETA, and Txa2 receptor antagonists on cyclosporine A renal vasoconstriction . Am J Physiol . 1994;267:F443–F449
  13. Benigni A , Perico N , Ladny JR , et al.   Increased urinary excretion of endothelin-1 and its precursor big endothelin-1 in rats chronically treated with cyclosporine . Transplantation . 1991;52:175–177
  14. Xin J , Homma T , Matsusaka T , et al.   Suppression of cyclosporine A nephrotoxicity in vivo by transforming growth factor B receptor immunoglobulin G chimeric protein . Transplantation . 2004;77:1433–1442
  15. Shihab FS , Bennett WM , Andoh TF . Effect of nitric oxide modulation on TGF- Beta1 and matrix proteins in chronic cyclosporine neprotoxicity . Kidney Int . 2000;58:1174–1185
  16. Racusen L , Solez K , Colvin R , et al.   The Banff 97 working classification of renal allograft pathology . Kidney Int . 1999;5:713–723
  17. Mihatsch MJ , Ryffel B , Gudat F . The differential diagnosis between rejection and cyclosporine toxicity . Kidney Int . 1995;48(suppl 52):S63–S69
  18. Mihatsch MJ , Thiel G , Ryffel B . Histopathology of cyclosporine nephrotoxicity . Transplantation Proc . 1988;20(suppl 3):759–771
  19. Murray BM , Paller MS . Beneficial effects of renal denervation and prazosin on GFR and renal blood flow after cyclosporine in rats . Clin Nephrol . 1986;25(suppl):S37–S39
  20. Churchill MC , Churchill PC , Bidani AK . The effects of cyclosporine in Lewis rats with native and transplanted kidneys . Transplantation . 1993;55:1256–1260
  21. Peters DH , Fitton A , Plosker GL , et al.   Tacrolimus (A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation) . Drugs . 1993;46:764–794
  22. Solez K , Racusen LC , Mihatsch M . Nephrotoxicity of cyclosporine and newer immunosuppressive agents . In:  Solez K ,  Racusen LC ,  Billingham M editor. Solid Organ Allograft Rejection . New York, NY: Marcel Dekker; 1996;p. 587–620
  23. Falkenheim ME , Cosio FG , Sedmak DD . Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine . Transplantation . 1996;62:364–370
  24. Myers BD , Sibley R , Newton L , et al.   The long-term course of cyclosporine associated chronic nephropathy . Kidney Int . 1988;33:590–600
  25. Zaltman JS , Pei Y , et al.   Cyclosporine nephrotoxicity in lung transplant recipients . Transplantation . 1992;54:875–878
  26. Nankivell B , Borrows RJ , Fung C , et al.   The natural history of chronic allograft nephropathy . N Engl J Med . 2003;349:2326–2333
  27. O’Grady JG , Forbes A , Rolles K , et al.   An analysis of cyclosporine efficacy and toxicity after liver transplantation . Transplantation . 1988;45:575–579
  28. Mourad G , Vela C , Ribstein J , et al.   Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy . Transplantation . 1998;65:661–667
  29. Gruessner RW , Burke GW , Stratta R , et al.   A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation . Transplantation . 1996;61:261–273
  30. Dieterle A , Gratwohl A , Nizze H , et al.   Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients . Transplantation . 1990;49:1093–1110
  31. Feutren G , Mihatsch MJ . International kidney biopsy registry of cyclosporine in autoimmune diseases. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases . N Engl J Med . 1992;326:1654–1660
  32. Krieger N , Becker B , Heisey D , et al.   Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related, and living-unrelated grafts . Transplantation . 2003;75:1677–1682
  33. Cecka JM . Then UNOS Scientific Renal Transplant Registry . In:  Cecka JM ,  Terasaki PI editor. Clinical Transplants 2000 . Los Angeles, CA: UCLA Immunogenetics Center; 2001;
  34. Melk A , Halloran P . Immunosuppressive agents used in transplantation . In:  Johnson RJ editors. Comprehensive Clinical Nephrology . Philadelphia, PA: Mosby; 2000;p. 1057–1069
  35. Melk A , Halloran P . Immunosuppressive Agents Used in Transplantation . In:  Johnson RJ editors. Comprehensive Clinical Nephrology . Philadelphia, PA: Mosby; 2000;p. 1057–1069
  36. Mahe E , Morelon E , Lechaton S . Cutaneous adverse events in renal transplant recipients receiving sirolimus based therapy . Transplantation . 2005;79:476–482
  37. Dean P , Lend W , Prieto M . Wound healing complications after kidney transplantation . Transplantation . 2004;77:1555–1561
  38. Morrisett J , Abdel-Fattah G , Kahan B . Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant patients . Transplant Proc . 2003;35:143S–150S
  39. Dittrich E , Schmeldeinst S , Soleiman A . Rapamycin associated post-transplantation glomerulonephritis and its remisssion after reintroduction of calcineurin-inhibition therapy . Transplant Int . 2004;17:215–220
  40. Kahan BD . Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomized multicentre study. The Rapamune U.S. Study Group . Lancet . 2000;356:194–202
  41. MacDonald AS . A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts . Transplantation . 2001;71:271–280
  42. Groth CG , Backman L , Morales JM , et al.   Sirolimus based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group . Transplantation . 1999;67:1036–1042
  43. Kreis H , Cisterne JM , Land W , et al.   Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients . Transplantation . 2000;74:v69:1252–1260
  44. Cole M , Maham N , Cardella C , et al.   Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients . Transplantation . 2003;75:2086–2090
  45. Sells RA , Bakran A , Brown MW , et al.   A prospective randomized study of CSA monotherapy versus CSA + mycophenolate mofetil in cadaveric renal recipients, in Program and Abstracts of the 3rd International Conference on New Trends in Clinical and Experimental Immunosuppression . 1998; Geneva, Switzerland, February 12-15
  46. Weir M , Anderson L , Fink J , et al.   A novel approach to the treatment of chronic allograft nephropathy . Transplantation . 1997;64:1706–1710
  47. Sanchez V , Delgado J , Morales R , et al.   Chronic cyclosporine-induced nephrotoxicity in heart transplant patients (Long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine) . Transplantation Proc . 2004;36:2823–2825
  48. Weir M , Blahut S , Drachenburg C , et al.   Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function . Am J Nephrol . 2004;24:379–386
  49. Dudley C , Pohanka E , Riad H , et al.   Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction (The “Creeping Creatinine” Study) . Transplantation . 2005;79:466–475
  50. RAPAMUNE (sirolimus) 3-year safety update, Protocol No. 0468H1-310-GL. Madison, NJ, Wyeth Pharmaceuticals
  51. Grinyo JM , Gil-vernet S , Cruzad JM . Calcineurin inhibitor free immunosuppression based on antithymocyte globulin and mycophenolate mofetilin cadaveric kidney transplantation . Transplant Int . 2003;16:820–827

PII: S1548-5595(05)00202-8

doi: 10.1053/j.ackd.2005.11.001

Advances in Chronic Kidney Disease
Volume 13, Issue 1 , Pages 47-55 , January 2006

Article Tools